Table 2 |
||||||||||||
|
Associations between OC or HRT use and breast cancer defined by ESR1 A908G mutation status |
||||||||||||
|
Risk factor |
Controls (n = 790) |
Mutation-positive cases (n = 37) |
Mutation-positive cases vs. controls |
Mutation-negative cases (n = 616) |
Mutation-negative cases vs. controls |
Mutation-positive vs. mutation-negative cases |
||||||
|
n |
(%) |
n |
(%) |
ORa |
95% CI |
n |
(%) |
ORa |
95% CI |
ORa |
95% CI |
|
|
|
||||||||||||
|
OC use |
||||||||||||
|
Never |
319 |
(40.4) |
14 |
(37.8) |
1.00 |
--- |
224 |
(36.5) |
1.00 |
--- |
1.00 |
--- |
|
Ever |
470 |
(59.6) |
23 |
(62.2) |
1.72 |
0.66–4.44 |
390 |
(63.5) |
1.15 |
0.87–1.52 |
1.53 |
0.61–3.84 |
|
OC duration |
||||||||||||
|
Never |
319 |
(40.4) |
14 |
(37.8) |
1.00 |
--- |
224 |
(36.5) |
1.00 |
--- |
1.00 |
--- |
|
<5 years |
232 |
(29.4) |
8 |
(21.6) |
1.08 |
0.35–3.38 |
194 |
(31.6) |
1.27 |
0.94–1.73 |
1.01 |
0.33–3.06 |
|
5–10 years |
162 |
(20.5) |
8 |
(21.6) |
1.75 |
0.53–5.77 |
123 |
(20.0) |
0.95 |
0.67–1.35 |
1.79 |
0.59–5.43 |
|
>10 years |
76 |
(9.6) |
7 |
(8.9) |
3.73 |
1.16–12.03 |
73 |
(11.9) |
1.18 |
0.77–1.81 |
2.66 |
0.81–8.67 |
|
Ptrend |
0.02 |
0.84 |
0.07 |
|||||||||
|
Age at first use of OCs |
||||||||||||
|
Never |
319 |
(40.4) |
14 |
(37.8) |
1.00 |
--- |
224 |
(36.6) |
1.00 |
--- |
1.00 |
--- |
|
≤20 years |
215 |
(27.2) |
8 |
(21.6) |
1.18 |
0.32–4.42 |
192 |
(31.4) |
0.99 |
0.69–1.41 |
1.44 |
0.41–5.09 |
|
>20 years |
255 |
(32.3) |
15 |
(40.5) |
1.81 |
0.71–4.63 |
196 |
(32.0) |
1.20 |
0.89–1.60 |
1.56 |
0.61–3.96 |
|
Age at last use of OCs |
||||||||||||
|
Never |
319 |
(40.4) |
14 |
(37.8) |
1.00 |
--- |
224 |
(36.6) |
1.00 |
--- |
1.00 |
--- |
|
≤30 years |
273 |
(34.6) |
10 |
(27.0) |
1.18 |
0.36–3.90 |
226 |
(36.9) |
1.10 |
0.80–1.52 |
1.39 |
0.45–4.25 |
|
>30 years |
197 |
(25.0) |
13 |
(35.1) |
1.97 |
0.75–5.15 |
162 |
(26.5) |
1.16 |
0.85–1.58 |
1.63 |
0.62–4.29 |
|
Year of first OC use |
||||||||||||
|
Never |
319 |
(40.4) |
14 |
(37.8) |
1.00 |
--- |
224 |
(36.6) |
1.00 |
--- |
1.00 |
--- |
|
≤1975 |
389 |
(49.3) |
19 |
(51.4) |
1.72 |
0.67–4.43 |
292 |
(47.7) |
1.15 |
0.87–1.52 |
1.54 |
0.61–3.89 |
|
>1975 |
81 |
(10.3) |
4 |
(10.8) |
1.51 |
0.28–8.12 |
96 |
(15.7) |
0.98 |
0.62–1.55 |
1.58 |
0.35–7.13 |
|
First use before first full-term pregnancy |
||||||||||||
|
No |
233 |
(54.8) |
11 |
(57.9) |
1.00 |
--- |
169 |
(51.1) |
1.00 |
--- |
1.00 |
--- |
|
Yes |
192 |
(45.2) |
8 |
(42.1) |
0.66 |
0.15–2.93 |
162 |
(48.9) |
1.12 |
0.76–1.66 |
0.78 |
0.18–3.31 |
|
Recency of OC use (years since stopping) |
||||||||||||
|
Never |
319 |
(42.3) |
14 |
(37.8) |
1.00 |
--- |
224 |
(39.4) |
1.00 |
--- |
1.00 |
--- |
|
10+ |
374 |
(49.5) |
17 |
(45.9) |
1.70 |
0.65–4.43 |
278 |
(48.8) |
1.15 |
0.86–1.52 |
1.52 |
0.59–3.92 |
|
<10 |
62 |
(8.2) |
6 |
(16.2) |
3.63 |
0.80–16.45 |
67 |
(11.8) |
1.06 |
0.65–1.72 |
3.65 |
0.86–15.47 |
|
Ptrend |
0.10 |
0.56 |
0.10 |
|||||||||
|
OC duration and recency of use (years since stopping) |
||||||||||||
|
Never |
319 |
(42.3) |
14 |
(37.8) |
1.00 |
--- |
224 |
(39.4) |
1.00 |
--- |
1.00 |
--- |
|
<10, <10 |
31 |
(4.1) |
2 |
(5.4) |
1.43 |
0.19–10.77 |
32 |
(5.6) |
0.84 |
0.44–1.58 |
3.04 |
0.46–20.06 |
|
<10, 10+ |
315 |
(41.7) |
13 |
(35.1) |
1.53 |
0.55–4.26 |
245 |
(43.1) |
1.21 |
0.90–1.62 |
1.25 |
0.46–3.41 |
|
10+, <10 |
31 |
(4.1 |
4 |
(10.8) |
6.49 |
1.32–31.89 |
35 |
(6.2) |
1.32 |
0.73–2.38 |
3.53 |
0.73–17.09 |
|
10+, 10+ |
59 |
(7.8) |
4 |
(10.8) |
1.93 |
0.52–7.11 |
33 |
(5.8) |
0.81 |
0.49–1.35 |
3.01 |
0.78–11.59 |
|
Postmenopausal HRT use |
||||||||||||
|
Never |
219 |
(50.3) |
13 |
(59.1) |
1.00 |
--- |
180 |
(61.0) |
1.00 |
--- |
1.00 |
--- |
|
Ever |
216 |
(49.7) |
9 |
(40.9) |
0.83 |
0.28–2.42 |
115 |
(39.0) |
0.62 |
0.44–0.87 |
1.23 |
0.42–3.61 |
|
Postmenopausal HRT duration |
||||||||||||
|
Never |
219 |
(50.3) |
13 |
(59.1) |
1.00 |
--- |
180 |
(61.0) |
1.00 |
--- |
1.00 |
--- |
|
<5 years |
105 |
(24.1) |
3 |
(13.6) |
0.60 |
0.14–2.51 |
56 |
(19.0) |
0.61 |
0.40–0.92 |
1.37 |
0.30–6.24 |
|
5+ years |
111 |
(25.6) |
6 |
(27.3) |
1.07 |
0.31–3.70 |
59 |
(20.0) |
0.64 |
0.42–0.96 |
1.17 |
0.35–3.91 |
|
|
||||||||||||
|
aORs adjusted for sampling fraction, age, race, menopausal status (where appropriate), first-degree family history of breast cancer, parity/age first full-term pregnancy, breast feeding (ever, never), smoking status (never, former, current), alcohol intake (ever, never), age at menarche (<11, 11–12, 13, 14+), and body mass index (<25, 25 to <30, 30+). CI, confidence interval; ESR1, estrogen receptor alpha; HRT, hormone replacement therapy; OC, oral contraceptive; OR, odds ratio. |
||||||||||||
|
Conway et al. Breast Cancer Research 2007 9:R36 doi:10.1186/bcr1731 |
||||||||||||
